Compare Mesoblast Limited (MESO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Meta Platforms Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Meta Platforms Inc trades at $646.5 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 755.8× Mesoblast Limited's market cap, and Meta Platforms Inc pays a 0.33% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | META | |
|---|---|---|
Market Cap | $2.17B | $1.64T |
Sector | Technology | Media |
52-Week High | $20.96 | $790.00 |
52-Week Low | $12.88 | $525.72 |
Enterprise Value | $2.17B | $1.65T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
META stock trades at $646.01, down 2.79% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $10.44 surpassing expectations of $6.70. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $807.17. Recent news highlights the launch of Muse Spark AI and a legal ruling in Massachusetts regarding youth addiction claims.
The outlook for META is favorable, driven by AI innovation and robust financials, but risks include regulatory lawsuits and high capital expenditures. With 79% of analysts rating it a buy and a price target implying 25% upside, the stock presents a growth opportunity, though investors should weigh legal and competitive pressures against its strong market position and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
